Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine

Journal of Medical Virology

Volumn 78, Issue 8, 2006, Pages 1043-1046

  Alexopoulou, Alexandra ^a,c   Dourakis, Spyros P ^a   Pandelidaki, Helen ^a   Archimandritis, Athanasios J ^a   Karayiannis, Peter ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NONE   (Greece)

Author keywords

Chronic lymphocytic leukaemia; Fludarabine; HBsAg variant; HBV reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGININE; ASPARAGINE; CYSTEINE; FLUDARABINE; GLYCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; SERINE; VIRUS DNA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ANTIGENIC VARIATION; ANTIGENICITY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC KIT; DNA DETERMINATION; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS STRAIN;

AGED; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MUTATION; PHYLOGENY; VIDARABINE;

HEPATITIS B VIRUS;

EID: 33745726967     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20660     Document Type: Article

References (26)

1. Alexopoulou A, Karayiannis P, Hadziyannis SJ, Aiba N, Thomas HC. 1997. Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol 26:748-753.
2. Alexopoulou A, Baltayiannis G, Jammeh S, Waters J, Dourakis SP, Karayiannis P. 2004. Hepatitis B surface antigen variant with multiple mutations in the a determinant in an agammaglobulinemic patient. J Clin Microbiol 42:2861-2865.
3. Aritomi T, Yatsuhashi H, Fujino T, Yamasaki K, Inoue O, Koga M, Kato Y, Yano M 1998. Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gastroenterol Hepatol 13:1125-1132.
4. Ashton-Rickardt PG, Murray K. 1989. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immuno-dominant a region. J Med Virol 29:196-203.
5. Brown SE, Howard CR, Zuckerman AJ, Steward MW. 1984. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet ii:184-187.
6. Bruce SA, Murray K. 1995. Mutations of some critical amino-acid residues in the hepatitis B surface antigen. J Med Virol 46:157-161.
7. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 236:325-329.
8. Chiou HL, Lee TS, Kuo J, Mau YC, Ho MS. 1997. Altered antigenicity of 'a' determinant variants of hepatitis B virus. J Gen Virol 78:2639-2645.
9. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. 1975. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2:528-530.
10. Grethe S, Monazahian M, Bohme I, Thomssen R. 1998. Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 72:7692-7696.
11. Harrison TJ, Hopes EA, Oon CJ, Zanetti AR, Zuckerman AJ. 1991. Independent emergence of a vaccine induced escape mutant of hepatitis B virus. J Hepatol 13:S105-S107.
12. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayiannis P, Luo K. 2001. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunised surface antigen-negative Chinese carriers. Hepatology 34:1027-1034.
13. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. 1997. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 26; 785-791.
14. Huang P, Chubb S, Plunkett W. 1990. Termination of DNA synthesis by 9-b-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265:16617-16625.
15. Karthigesu VD, Allison LM, Fortuin M, Mendy M, Whittle HC, Howard CR. 1994. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 75:443-448.
16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy, report of a prospective study. Gastroenterology 100:182-188.
17. McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, Nadler PI, Ostberg L. 1992. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 15:757-766.
18. Mondelli M, Vergani GM, Alberti A, Vergani D, Portmann B, Eddleston AL, Williams R. 1982. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129:2773-2778.
19. Papaevangelou G, Karaboyia-Karafyllidis P, Kyriakidou A. 1977. Prevalence and epidemiologic significance of antibody to hepatitis B core antigen in Greece. Am J Epidemiol 106:502-506.
20. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108.
21. Rossi G. 2003. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 44:759-766.
22. Rossi G, Pelizzari A, Motta M, Puoti M. 2001. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115:58-62.
23. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, Thomas HC. 1992. Loss of the common 'a' determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 90:2543-2547.
24. Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M. 1994. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68:2671-2676.
25. Yeo W, Chan PK, ZhongS, Ho WM, Steinberg JL, Tarn JS, Hui P, Leung NW, Zee B, Johnson PJ. 2000. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307.
26. Zhang YY, Nordenfelt E, Hansson BG. 1996. Increasing heterogeneity of the 'a' determinant of HBsAg found in the presumed late phase of chronic hepatitis B virus infection. Scand J Infect Dis 28:9-15.